12:21 EDT Novavax (NVAX) falls 4% to $5.76 after WSJ report on unlikely approval
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
- Unusually active option classes on open March 31st
- Vaccine, gene therapy makers fall after Peter Marks resignation
- U.S. to end funding for child vaccines in developing countries, NY Times reports
- Novavax call volume above normal and directionally bullish